Celldex Therapeutics
CLDX
91 hedge funds and large institutions have $477M invested in Celldex Therapeutics in 2020 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 26 increasing their positions, 14 reducing their positions, and 20 closing their positions.
178% more call options, than puts
Call options by funds: $11M | Put options by funds: $3.97M
86% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 14
75% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 20
31% more capital invested
Capital invested by funds: $365M → $477M (+$112M)
20% more funds holding
Funds holding: 76 → 91 (+15)
3.86% more ownership
Funds ownership: 77.19% → 81.05% (+3.9%)
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Polar Capital
London,
United Kingdom
|
+$14.6M |
| 2 |
VA
VR Adviser
New York
|
+$9.37M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$6.38M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$6.26M |
| 5 |
RI
RTW Investments
New York
|
+$5.98M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$9.37M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$9.34M |
| 3 |
EP
Eversept Partners
New York
|
-$6.59M |
| 4 |
CA
Corriente Advisors
Fort Worth,
Texas
|
-$5.98M |
| 5 |
Millennium Management
New York
|
-$5.6M |
CLDX Hedge Fund Activity: Q3 2020 in Review
91 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q3 2020, worth a combined $477M — up 31% from $365M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new CLDX positions and 20 closed out — a net gain of 15 holders — while 26 added to existing stakes and 14 trimmed.
The largest buyer was Polar Capital, opening a new position worth an estimated $14.6M. The largest seller was Logos Global Management, cutting an estimated $9.37M.
- 91 institutional investors held Celldex Therapeutics (CLDX) as of Q3 2020, up from 76 in Q2 2020.
- Funds reported $477M of Celldex Therapeutics stock for Q3 2020, up 31% quarter-over-quarter.
- 35 funds opened new Celldex Therapeutics positions in Q3 2020 and 20 closed out, a net change of +15 holders.
- The largest Celldex Therapeutics buyer in Q3 2020 was Polar Capital, an estimated $14.6M added.
- The largest Celldex Therapeutics seller in Q3 2020 was Logos Global Management, an estimated $9.37M sold.
Based on aggregated 13F filings for Q3 2020.